Moleculin Highlights Annamycin’s Non-Cardiotoxic Profile to Support Phase 3 AML Trial
Moleculin released a CEO Corner segment highlighting Annamycin’s demonstrated non-cardiotoxic profile across preclinical and clinical studies, addressing cardiotoxicity limitations of traditional anthracyclines such as doxorubicin. This safety advantage could broaden use in relapsed/refractory AML and advanced solid tumors and strengthen commercial positioning as the Phase 3 MIRACLE trial advances.
1. CEO Corner Release
Moleculin debuted the latest CEO Corner segment featuring Walter Klemp, focusing on Annamycin’s therapeutic potential and safety differentiators over standard anthracyclines.
2. Annamycin Safety Profile
Klemp emphasized non-cardiotoxic outcomes observed in both preclinical and clinical trials, underscoring Annamycin’s design to prevent cardiac damage common with doxorubicin.
3. MIRACLE Phase 3 Trial Progress
The company is advancing its adaptive MIRACLE (MB-108) Phase 3 trial in relapsed or refractory acute myeloid leukemia, leveraging safety data to support efficient patient recruitment and regulatory engagement.
4. Commercial and Regulatory Outlook
The differentiated safety profile may enable broader prescribing in AML and solid tumors, bolster market adoption and reinforce the case for accelerated regulatory pathways.